The Federal Trade Commission approved Baxter‘s (NYSE:BAX) $625 million acquisition of Claris Lifesciences‘ (BOM:533288) injectable drug biz, but mandated that the companies divest two drugs products – an antifungal agent, fluconazole, and intravenous milrinone.
The FTC filed a complaint saying that the original deal would likely reduce competition in the U.S. for fluconazole since Baxter and Claris represent two of the four significant competitors selling fluconazole in saline intravenous bags. Combined, they hold an estimated market share of 60%, according to the FTC.
Get the full story at our sister site, Drug Delivery Business News.
The post FTC approves Baxter’s $625m Claris buyout, with conditions appeared first on MassDevice.